Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: An exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study

Journal of Clinical Pharmacy and Therapeutics

Volumn 41, Issue 3, 2016, Pages 298-305

  Hosoya, T ^a   Sasaki, T ^b   Hashimoto, H ^c   Sakamoto, R ^c   Ohashi, T ^b  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Fuji Yakuhin Co Ltd   (Japan)

^c SANWA KAGAKU KENKYUSHO CO LTD   (Japan)

Author keywords

gout; hyperuricemia; topiroxostat

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BETA 2 MICROGLOBULIN; BILIRUBIN; COLCHICINE; CREATINE KINASE; CREATININE; GAMMA GLUTAMYLTRANSFERASE; N ACETYL BETA GLUCOSAMINIDASE; PLACEBO; TOPIROXOSTAT; TRIACYLGLYCEROL; URATE; ANTIGOUT AGENT; FYX-051; NITRILE; PYRIDINE DERIVATIVE; URIC ACID; XANTHINE OXIDASE;

ADULT; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EXPLORATORY RESEARCH; FEMALE; GLOMERULUS FILTRATION RATE; GOUT; HEADACHE; HUMAN; HYPERURICEMIA; INCIDENCE; JAPANESE (PEOPLE); JONCKHEERE TERPSTRA TEST; KIDNEY FUNCTION; LABORATORY TEST; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; STOMATITIS; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT WITHDRAWAL; URIC ACID BLOOD LEVEL; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; FOLLOW UP; JAPAN; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; JAPAN; MALE; MIDDLE AGED; NITRILES; PYRIDINES; TREATMENT OUTCOME; URIC ACID; XANTHINE OXIDASE;

EID: 84963589383     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12392     Document Type: Article

References (26)

1. Li-Yu J, Clayburne G, Sieck M, et al,. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol, 2001; 28: 577-580.
2. Shoji A, Yamanaka H, Kamatani N,. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum, 2004; 51: 321-325.
3. Hall AP, Barry PE, Dawber TR, McNamara PM,. Epidemiology of gout and hyperuricemia. A long-term population study. Am J Med, 1967; 42: 27-37.
4. Campion EW, Glynn RJ, DeLabry LO,. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med, 1987; 82: 421-426.
5. Høieggen A, Alderman MH, Kjeldsen SE, et al,. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int, 2004; 65: 1041-1049.
6. Siu YP, Leung KT, Tong MK, Kwan TH,. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis, 2006; 47: 51-59.
7. Goicoechea M, de Vinuesa SG, Verdalles U, et al,. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol, 2010; 5: 1388-1393.
8. Franse LV, Pahor M, Di Bari M, et al,. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens, 2000; 18: 1149-1154.
9. Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM,. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke, 2006; 37: 1503-1507.
10. Newman EJ, Rahman FS, Lees KR, Weir CJ, Walters MR,. Elevated serum urate concentration independently predicts poor outcome following stroke in patients with diabetes. Diabetes Metab Res Rev, 2006; 22: 79-82.
11. Arellano F, Sacristán JA,. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother, 1993; 27: 337-343.
12. Hande KR, Noone RM, Stone WJ,. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med, 1984; 76: 47-56.
13. Becker MA, Schumacher HR Jr, Wortmann RL, et al,. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med, 2005; 353: 2450-2461.
14. Matsumoto K, Okamoto K, Ashizawa N, Nishino T,. FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase. J Pharmacol Exp Ther, 2011; 336: 95-103.
15. Sato T, Ashizawa N, Matsumoto K, et al,. Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051-a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected]. Bioorg Med Chem Lett, 2009; 19: 6225-6229.
16. Nakazawa T, Iwanaga T, Ohashi T, et al,. Pharmacokinetics and pharmacodynamics study of topiroxostat by oral administration in subjects with renal impairment. Jpn Pharmacol Ther, 2015; 43: 639-645.
17. Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, Mulford DJ,. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther, 2005; 12: 22-34.
18. Nakazawa T, Miyata K, Omura K, Iwanaga T, Nagata O,. Metabolic profile of FYX-051 (4-(5-pyridin-4-yl-1 h-[1,2,4]triazol-3-yl)pyridine-2-carbonitrile) in the rat, dog, monkey, and human: identification of N-glucuronides and N-glucosides. Drug Metab Dispos, 2006; 34: 1880-1886.
19. Hosoya T, Ohno I, Nomura S, et al,. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. Clin Exp Nephrol, 2014; 18: 876-884.
20. The Guideline Committee of Japanese Society of Gout, Nucleic Acid Metabolism. Guideline for the management of hyperuricemia and gout 1st edition: The classification of hyperuricemia (in Japanese). Tokyo: Dentsu Sudler & Hennessey Inc., 2002. 20 p.
21. Yamanaka H, Togashi R, Hakoda M, et al,. Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol, 1998; 431: 13-18.
22. Matsuo S, Imai E, Horio M, et al,. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis, 2009; 53: 982-992.
23. Kamatani N, Fujimori S, Hada T, et al,. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in Japan: late phase 2 clinical study. J Clin Rheumatol, 2011; 17: S35-S43.
24. Kashihara N, Watanabe Y, Makino H, Wallner EI, Kanwar YS,. Selective decreased de novo synthesis of glomerular proteoglycans under the influence of reactive oxygen species. Proc Natl Acad Sci USA, 1992; 89: 6309-6313.
25. Sircar D, Chatterjee S, Waikhom R, et al,. Efficacy of febuxostat for slowing the GFR decline in patients With CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, Placebo-Controlled Trial. Am J Kidney Dis, 2015; 66: 945-950.
26. Utami SB, Mahati E, Li P, Maharani N, et al,. Apoptosis induced by an uromodulin mutant C112Y and its suppression by topiroxostat. Clin Exp Nephrol, 2015; 19: 576-584.